A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 330 participants.

Also called NCT07112872

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 330 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07112872
  • EU CT 2024-520322-11-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Hungary, Poland, Spain (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07112872. Randomized; double masking; primary purpose treatment. Start 2025-08-19 (actual); primary completion 2028-02-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Tifeglipron
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo
Lead sponsor
Hoffmann-La Roche (class: industry)

Record details

Record id
cardio:ct-nct07112872
Content hash
d04ccc808e36e8ff7c4ed89f790077632b8df95ef2ce80bf17ef0e9dc8323219